# ARASTEP (NCT05794906)

> A Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) and Placebo Given With ADT in Men With Hormone Sensitive Prostate Cancer and Raise of Prostate Specific Antigen (PSA) Levels After Local Therapies

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05794906
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Bayer
- Conditions: Biochemically Recurrent Prostate Cancer
- Interventions: Darolutamide (BAY1841788, Nubeqa); Placebo matching darolutamide; ADT
- Enrollment: 985
- Primary outcome: Radiological progression-free survival (rPFS) by Prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) assessed by Blinded independent central review (BICR)

## Commentary we found

- X threads: 9
- YouTube: 5
- Podcasts: 3

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=arastep-nct05794906

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT05794906", "email": "<work email>"}; the inbox owner confirms by the emailed link.